1-(4-Fluoro-5-methyl-2-nitrophenyl)-4-[4-(trifluoromethyl)benzoyl]piperazine

Catalog No. :
ACMKZE866
CAS No. :
1262222-55-8
Molecular Formula :
C19H17F4N3O3
Molecular Weight :
411.36

IUPAC Name:(4-(4-fluoro-5-methyl-2-nitrophenyl)piperazin-1-yl)(4-(trifluoromethyl)phenyl)methanone

1-(4-Fluoro-5-methyl-2-nitrophenyl)-4-[4-(trifluoromethyl)benzoyl]piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(4-Fluoro-5-methyl-2-nitrophenyl)-4-[4-(trifluoromethyl)benzoyl]piperazine
IUPAC Name(4-(4-fluoro-5-methyl-2-nitrophenyl)piperazin-1-yl)(4-(trifluoromethyl)phenyl)methanone
MDL No.MFCD18204647
Molecular FormulaC19H17F4N3O3
Molecular Weight411.36
SMILESO=C(N1CCN(C2=CC(C)=C(F)C=C2[N+]([O-])=O)CC1)C3=CC=C(C(F)(F)F)C=C3
InChI KeyNJJJSRINLYPEHF-UHFFFAOYSA-N
Synonym1-(4-fluoro-5-methyl-2-nitrophenyl)-4-[4-(trifluoromethyl)benzoyl]piperazine;Methanone, [4-(4-fluoro-5-methyl-2-nitrophenyl)-1-piperazinyl][4-(trifluoromethyl)phenyl]-
CAS No.1262222-55-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACMKZE866 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEASN653 route compound structure diagram
    ACEASN65325832-58-0 In Stock
  4. Then
  5. ACMKZE866 route product structure diagram
    ACMKZE8661262222-55-8
Inquiry

2. ACMKZE866 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMKZE866 route product structure diagram
    ACMKZE8661262222-55-8
Inquiry

Comments (0)